With a more convenient dosing schedule of once every eight weeks, fewer episodes of breakthrough hemolysis through a more reliable C5 blockade, and lower cost, ravulizumab became an attractive option for patients with PNH who qualify for complement inhibition therapy22-24. Here, C5 is linked to paroxysmal nocturnal hemoglobinuria.